Is propranolol appropriate for treating performance‑related social anxiety (e.g., public speaking) in an adult without contraindications such as asthma, severe bradycardia, or heart block?

Propranolol for Performance-Related Social Anxiety

Propranolol can be used for performance-related social anxiety (such as public speaking), but it is not a guideline-recommended first-line treatment and lacks robust evidence for generalized social anxiety disorder. The most recent Japanese clinical practice guideline (2023) recommends SSRIs and cognitive behavioral therapy as primary treatments for social anxiety disorder, with no mention of propranolol or beta-blockers in their formal recommendations 1.

Evidence-Based Treatment Hierarchy

First-Line Treatments (Guideline-Recommended)

The 2023 Japanese guideline explicitly recommends:

• SSRIs (fluvoxamine, paroxetine, escitalopram) - weak recommendation, low certainty evidence 1
• SNRIs (venlafaxine) - weak recommendation, low certainty evidence 1
• Cognitive Behavioral Therapy - specifically Clark and Wells or Heimberg models 1

Propranolol's Limited Role

For situational/performance anxiety only: Propranolol may be useful for acute, predictable performance situations (public speaking, specific social phobias limited in number) at doses of 20-40 mg, taken 1-3 times daily 2. However, this represents off-label use with limited supporting evidence.

Key limitations:

• A 2025 meta-analysis found no evidence of beneficial effect for propranolol versus placebo or benzodiazepines in social phobia or panic disorder (p ≥ 0.54 for all comparisons) 3
• A 2016 systematic review concluded there is insufficient evidence to support routine use of propranolol for any anxiety disorder 4
• A 2020 study on public speaking anxiety showed propranolol did not reliably outperform placebo regardless of speech duration 5

Mechanism and Practical Considerations

Propranolol works by blocking peripheral adrenergic symptoms (tremor, tachycardia, sweating) rather than treating core anxiety 2, 6. It reduces observable physical manifestations but may not address subjective distress.

Dosing for performance anxiety (when used):

• 20-40 mg taken 30-60 minutes before the performance
• Single-dose or short-term use only
• Efficacy beyond 4 weeks is undemonstrated 2

Critical Safety Contraindications

Before considering propranolol, absolutely exclude 7:

• Asthma or bronchospastic lung disease (can provoke severe bronchospasm)
• Bradycardia or heart block (greater than first-degree)
• Cardiogenic shock
• Congestive heart failure (can precipitate cardiac failure)
• Diabetes (masks hypoglycemia warning signs)
• Hyperthyroidism (masks symptoms, risk of thyroid storm on withdrawal)

Clinical Algorithm

For performance-limited social anxiety:

1. If symptoms are persistent (>6 months) or cause significant impairment → Start SSRI + consider CBT 1
2. If symptoms are truly situational and infrequent → Propranolol 20-40 mg as needed may be considered off-label, only after excluding contraindications
3. Monitor for cognitive impairment (propranolol may impair memory recall of difficult items) 8

Common pitfall: Propranolol is increasingly prescribed for anxiety despite lack of robust evidence 3. The 2023 guideline's omission of beta-blockers from recommendations is telling—they prioritized treatments with demonstrated efficacy for quality of life and symptom reduction.

Bottom line: While propranolol has historical use for performance anxiety and reduces visible physical symptoms, current high-quality evidence does not support it as an effective treatment for social anxiety disorder. SSRIs and CBT remain the evidence-based choices for meaningful improvement in anxiety symptoms and quality of life.